Tantech Holdings Ltd.'s board approved a reverse stock split of its Class A common shares at a ratio of 1-for-50. The transaction is effective on September 3, 2026, with split-adjusted trading commencing on September 4, 2026. Outstanding shares will decrease from approximately 33.38 million to roughly 667,647, with no fractional shares issued. This company operates in the technology and investment sector.

Tantech Holdings Ltd announced the resignation of independent directors Shudong Wang and Mengqi Liao effective August 12, 2026. The resignations were not due to disagreements regarding operations or policies. To fill these vacancies, the Board elected Jiwen Huang and Chuanjiang Xiao as new independent directors and members of the nominating committee. Mr. Huang brings experience from Xinjiang Shihezi City Lisheng Medical Device Sales Co., Ltd., while Mr. Xiao serves as CEO of Sichuan Chaihuo Shidai Business Information Consulting Co., Ltd. Both new directors meet Nasdaq independence requirements. Tantech Holdings Ltd operates in the medical device industry.

Tantech Holdings Ltd reported that Mr. Weilin Zhang and Mr. Hongdao Qian resigned as directors effective August 2, 2026, citing no disagreements with the company. The board appointed Mr. Yongxin Su as Co-CEO and Class III director, Ms. Pi-Hua Liu as Co-CFO to fill Mr. Zhang's vacancy, Mr. Lei Yao as an independent director and nominating committee chair to replace Mr. Qian, and Mr. Shipu Huang as an independent Class I director. The company operates in the technology sector.

Effective August 2, 2026, Weilin Zhang and Hongdao Qian resigned as directors of Tantech Holdings Ltd. The board elected Yongxin Su as a director and Co-Chief Executive Officer, Bihua Liu as a director and Co-Chief Financial Officer, Lei Yao as an independent director and chair of the nominating committee, and Shipu Huang as an independent director. These appointments fill vacancies resulting from the resignations. Tantech Holdings Ltd operates in the technology sector.